Stock detail

EİS Eczacıbaşı İlaç Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş.

ECILCSTOCKS | TR | IST | Healthcare | Drug Manufacturers - Specialty & Generic

Profile snapshotTRY 49.3Market cap TRY 33.8B

No local candle data found.

Recent detected patterns / setups

Latest 10 Market Radar results for this symbol and selected direction.

PatternTFScan runQuality

BullishOliver Kell Momentum Setup4H07 Nov 26, 16:1675

BullishICT Inverse FVG Setup4H07 Nov 26, 16:1682

BullishMA 8/21 Crossover4H07 Nov 26, 16:1684

BearishFibonacci Retracement Setup4H07 Nov 26, 16:16100

BullishMA 8/21 Crossover15M07 Nov 26, 09:1475

BullishSupport/Resistance Flip Setup15M07 Nov 26, 09:1478

BullishOliver Kell Momentum Setup15M07 Nov 26, 09:1482

BullishICT Order Block Setup15M07 Nov 26, 09:1486

BullishMA 21/55 Crossover15M07 Nov 26, 09:1487

BearishICT Optimal Trade Entry (OTE) Setup15M07 Nov 26, 09:1488

About EİS Eczacıbaşı İlaç Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş.

EİS Eczacıbaşı İlaç Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş. (ECILC) is listed on IST. Sector: Healthcare. Industry: Drug Manufacturers - Specialty & Generic.

EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S., together with subsidiaries, engages in health and real estate development businesses in Turkey and internationally. The Health segment is involved in the production, marketing, and sale of medicines related to human health and veterinary medicines. The Real Estate Development segment engages in development of real estate properties; rental activities for serum facilities; and providing consulting services on land development and project management. The company was incorporated in 1951 and is based in Istanbul, Turkey. EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a subsidiary of Eczacibasi Holding A.S.

Annual

Annual fundamentals

2025 vs previous annual period

Total revenueTRY 9.9B-14.0%

Net incomeTRY 2.1B+55.9%

Net profit margin21.2%+9.5 pp

EPS3.05+55.6%

Total debtTRY 3.2B-24.5%

Cash and cash equivalentsTRY 4.5B+44.8%

Net debtTRY -1.4B-228.4%

Metric20212022202320242025

Total revenue----TRY 3.5B--TRY 9.4B+169.9%TRY 11.5B+22.7%TRY 9.9B-14.0%

Net income----TRY 3B--TRY 4B+32.6%TRY 1.3B-66.1%TRY 2.1B+55.9%

Net profit margin----86.1%--42.3%-50.9%11.7%-72.4%21.2%+81.2%

EPS----4.35--5.77+32.5%1.96-66.0%3.05+55.6%

Free cash flow----TRY -1.2B--TRY 2.2B+278.2%TRY 2.1B-4.3%TRY 1.1B-47.4%

Total debt----TRY 3.2B--TRY 4.4B+38.0%TRY 4.2B-5.9%TRY 3.2B-24.5%

Cash and cash equivalents----TRY 916.4M--TRY 2.9B+216.3%TRY 3.1B+7.8%TRY 4.5B+44.8%

Net debt----TRY 2.3B--TRY 1.6B-32.8%TRY 1.1B-31.5%TRY -1.4B-228.4%

Quarterly

Quarterly fundamentals

Q3 2026 vs same quarter previous year

Total revenueTRY 2.4B+7.0%

Net incomeTRY -542.1M+28.7%

Net profit margin-22.6%+11.3 pp

EPS-0.79+28.8%

Total debtTRY 4.7B+20.1%

Cash and cash equivalentsTRY 2.5B+16.5%

Net debtTRY 2.3B+24.2%

MetricQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026

Total revenue----TRY 2.9B--TRY 3B--TRY 2.7B--TRY 2.2B--TRY 2.4B-18.0%

Net income----TRY 643M--TRY -481.7M--TRY -924M--TRY -760.5M--TRY -542.1M-184.3%

Net profit margin----22.0%---16.3%---33.6%---34.0%---22.6%-202.8%

EPS0.58--0.94-------1.35---1.11-291.4%-0.79-184.0%

Free cash flow----TRY -991.7M--TRY 116.2M--TRY -612.2M--TRY 1.9M--TRY 3.6B+464.7%

Total debt----TRY 3.7B--TRY 3.2B--TRY 3.9B--TRY 4B--TRY 4.7B+29.1%

Cash and cash equivalents----TRY 5.1B--TRY 4.5B--TRY 3.7B--TRY 2.1B--TRY 2.5B-51.2%

Net debt----TRY -1.4B--TRY -1.4B--TRY 191.1M--TRY 1.8B--TRY 2.3B+262.4%

Ownership

Institutional ownership summary

2026 Q4, quarter ended 2026-11-07

PeriodOwnershipInstitutions13F sharesTotal investedPositions